With the vast technological and informational resources increasingly available from investments in "genomics," toxicology and much of biological science, is faced with previously undreamed of opportunities and equally daunting challenges. The ability to generate the large quantities of data becoming routinely available could not be imagined a decade ago. The complexities of data analysis are increasingly the rate-limiting element in scientific advances. The expectations that these large scientific investments will reduce the incidence of human disease and improve health are very high. An emphasis on genetic variation and Toxicogenetics is expected to yield risk estimates for specific rather than average individuals and individuals with varied lifestyles and complex patterns of exposure. Examples from studies of polymorphic variation in DNA repair genes in the healthy population and cancer risk highlight the complexity and challenges of incorporating genetic variation into quantitative estimates of risk associated with environmentally relevant exposures. Similar issues exist in selecting the animal models most appropriate for predicting human risk from environmental exposures to toxic agents.
TOXICOLOGY AND GENOMICS A major overarching focus of toxicological research is the identification of disease causing agents, coupled with emphasis on understanding the cellular mechanism(s) for converting an exposure into a toxic response or disease. The development of increasingly sensitive experimental models for predicting or detecting the toxicity of compounds has resulted in the generation of long lists of "agents of interest." In parallel, sophisticated and highly sensitive analytical techniques have been developed, leading to assays capable of detecting increasingly lower levels of environmental chemicals. With the ever-increasing ability to detect a growing number of potentially toxic compounds in the human environment, the issues surrounding dose/response and levels of risk from relevant exposures are becoming paramount. Following in the steps of the success of the Human Genome Project, a number of "omics" projects, including the Toxicogenomics Project, have been proposed or initiated. These "omics" projects, to the extent that they emulate the Human Genome Project, are the application of high-throughput technology to generate data on a global scale. These "industrial scale" data generation efforts have several general characteristics. The approach is very focused on milestones for data generation rather than addressing specific hypotheses, the raw data are in the public domain and data analyses are often conducted by a larger community than generated the data. Thus, toxicogenomics can be described as an endeavor to elucidate the extent to which a wide range of cellular processes are involved in the biological responses of or-ganisms to environmental toxicants/stressors. The National Institute of Environmental Health Sciences (NIEHS) has recently initiated such a coordinated, multi-disciplinary research program, The National Center for Toxicogenomics ( http://www.niehs.nih.gov/nct/home.htm ), with a goal of obtaining large amounts of gene expression data relevant to toxicology. These initiatives have the potential to make substantial contributions to our understanding of the cellular mechanisms underlying toxic responses (Orphanides, 2003; Amin et al., 2002) . As with the Human Genome Project, toxicogenomics is generally a new approach to research and specifically a strategy emphasizing data generation, rather than new science. The questions and hypotheses of interest to toxicology, i.e., risk estimation, have been with us for some time.
Toxicology and Genetics
Many of the key questions in toxicology are related to issues of extrapolation from experimental models and estimation of human risk. This discussion will focus on the new opportunities available, but also the significant challenges faced in quantifying the relationship of exposure to adverse response and disease incidence in the human population. The emphasis for toxicology is increasingly to estimate the exposure-response relationship for the individual or population subsets rather than identifying agents that are associated with toxicity in either the "average" or the more sensitive individual. It should be clear that the issues involved in estimating exposure-related risk for "nonaverage" individuals are not dissimilar to issues in the choice of appropriate experimental models for toxicology testing. The focus of this discussion will be the contribution of genetic variation to individual risk from exposure, the Toxicogenetics arena. The examples of variation in DNA repair genes and cancer risk were selected to present concepts and the general state of research in this area and are not intended to be a comprehensive review of this specific area. These principles are generally relevant to most common human diseases, e.g., cancer, asthma, cardiovascular disease, infectious disease, in that for most of the individuals in the population, being affected with an adverse reaction or a disease is a consequence of the interaction of individual genetic susceptibility and exposure (e.g., Doris, 2002; Steinke et al., 2003; Turner and Boerwinkle, 2003) .
Drug Metabolism: A Model for Genetic Variation and Adverse Response
Pharmacogenetics has a rich history of relating genetic variation and adverse response to exposure. Several wellcharacterized examples from this area provide reference points for the present discussion of genetic variation and response to agents of toxicological interest. Genetic variation and the associated impact on response to administration of drugs have been extensively reviewed (e.g., Weinshilboum, 2003; Evans and McLeod, 2003) and especially the pharmacogenetic aspects of the drug metabolizing enzymes (Daly, 2003 ). An almost classic example is the relationship of genetic variation in the enzyme, thiopurine methyltransferase, with the efficacy and toxicity of the thiopurine drugs (Weinshilboum, 2001) . Individuals with reduced activity variants of this enzyme are at elevated risk of drug induced toxicity from standard treatment regimes. These same dosages have reduced efficacy in other individuals with hyperactive variants of this enzyme, as the drug is rapidly inactivated in these individuals. Other well-characterized examples of clinically relevant variation include the genes in the CYP3A family and CYP2D6 (Rogers et al., 2002; Flockhart and Rae, 2003) , genes encoding proteins with roles in the activation and detoxification or inactivation of many drugs. Recent reviews and commentaries discuss the current state of application of pharmacogenetics in the clinical laboratory and medical practice (Wolf et al., 2000; Ingelman-Sundberg and Evans, 2001; Kalow, 2001; Shi et al., 2001; Zanger et al., 2001; Kalow, 2002; Evans, 2003) .
The potential for individualized medicine has been extensively discussed (Anderson et al., 2003; Kurth, 2003; Oscarson, 2003; Siest et al., 2003) . Although the level of excitement regarding the potential for large-scale application of pharmacogenetics to clinical practice is high, some suggest a somewhat more tempered contribution to medical practice (Cooper and Psaty, 2003; Lindpaintner, 2003) . A common aspect of these examples of the successes of pharmacogenetics is the involvement of a single gene with primary responsibility for the activation and/or detoxification of a drug, coupled with the existence of a small number of variants with a significant impact on the level of enzyme activity. The role of defined and controlled exposures and also readily recognized differences in outcome are other important elements in the identification of the association of genetic variation and response. Thus, under these very well-defined conditions, with careful observation and knowledge of the relevant drug metabolizing pathway, it was relatively straightforward to relate genotype to phenotype or individual adverse response. One noteworthy aspect of these examples is the generally small number of individuals in the population for which this story of a genetic variant being associated with a major adverse response is apparently relevant.
Genetics and Disease
The contribution of genetics to variation in disease risk is easily recognized when the differential incidence or response is dramatic and inherited as a highly penetrant Mendalian trait. For example, genetic variation influencing disease incidence is readily observed in cancer families as will be described later. These families have multigenerational cancer incidences that are very obviously higher than observed in the general population. The colon and breast cancer families have been some of the most studied. A common aspect of the disease in these cancer families is the high penetrance of the disease phenotype. That is, individuals with the mutant gene usually are affected with the disease. In addition, these individuals are characterized with early age-of-onset of disease and the disease occurs in individuals without obvious exposures. In these families, specific variants at a locus are often associated with more than a 50-100-fold elevation in relative risk of disease, as compared with the general population. Study of these families has been very important in identifying genes with roles in cancer risk. Studies of the aberrant cellular biology that places these cells on a tumorogenic pathway have provided insight into the pathology of the disease. It has provided knowledge of both the function(s) of genes and the mechanisms and biological processes involved in tumor development. These studies have resulted in identification of genes with important roles in regulation of cell proliferation and/or maintenance of genomic integrity, where loss of function alleles are associated with very high risk of cancer. Similar families are known for the other common diseases, e.g., cardiovascular, diabetes.
Most common human diseases are not the consequence of variation in single genes. The disease associated alleles at these loci account for no more than 5% of the cancer cases. The situation is similar for the other common diseases in the population. Individuals (and cells) with variant alleles associated with highly penetrant disease, provide important models for studies of disease mechanisms, but explain only a small fraction of the health burden and disease incidence in the general population. Similarly, large exposures (at least for the last several decades) have not been major contributors to the cancer incidence in industrialized countries.
Screening for DNA Sequence Variation in the General Population
The Genome Program has provided the tools and resources to quantify what we have always observed. That is, species and strains of organisms differ, as do subpopulations, families and individuals within the human population. Much has been made recently of how similar "we" are at the level of the genomic sequence, both as groups within a population and also different species. But, it is unlikely that many fully appreciated the degree of individualization of people until the systematic resequencing of genes in unrelated individuals in the general U.S. population was initiated. Of specific relevance to this discussion, the technology and background information (e.g., DNA sequencing capacity, genomic sequence) developed by the Genome Programs provide a platform for a "Genotype-to-Phenotype" approach to toxicogenetics (and pharmacogenetics) and disease susceptibility . TOXICOLOGIC PATHOLOGY Several groups have initiated efforts to systematically screen for DNA sequence variation in genes. Most of these efforts have screened samples (usually the first 90 samples) from the DNA Polymorphism Discovery Resource collection, a set of 450 samples selected by the NIH to be representative of the major ethnic diversity of the U.S. population (Collins et al., 1998) . The DNA donors are anonymous, but expected to be generally healthy individuals. In keeping with the spirit of the Human Genome Project, data from these efforts are at several web sites: http://greengenes.llnl.gov/dpublic/secure/reseq/ , http:// www.genome.washington.edu/projects/egpsnps/ , http:// egp.gs.washington.edu , http://manuel.niehs.nih.gov/egsnp/ home.htm , http://pga.gs.washington.edu , and http:// www.genome.utah.edu/genesnps/ . These sites provide catalogs of the variants observed in systematically resequencing over 450 genes (as of 06/01/03). Many of the genes have roles in cellular processes involved in carcinogenesis or inflammation, both diseases where exposure and lifestyle as well as genetics contribute to the population incidence of disease.
The emphasis of these directed resequencing efforts have been the gene coding regions and amino acid substitutions as these are the sequence variants with highest potential to impact protein structure and activity, although silent SNPs (Single Nucleotide Polymorphism) and SNPs in noncoding segments are identified and reported. Much of the directed resequencing effort has been supported by the NIEHS Environmental Genome Project (EGP) ( http://www.niehs.nih.gov/envgenom/home.htm ), a project focusing on the role of genetic variation in the individual response or risk of disease following exposure to environmentally relevant agents. Similar research in the area of individual variation in response to pharmacological agents can be reviewed through the Pharmacogenetics Research Network ( http://www.nigms.nih.gov/pharmacogenetics/index. html ). Both of these sites have excellent tutorials on both the potential impact of genetic variation and genes and pathways with roles in toxicogenetics and pharmacogenetics.
Several examples will illustrate the range of genes selected for screening and the level of individual DNA sequence variation observed in these systematic screens of 90 individuals from the U.S. population. Fifty amino acid substitution variants have been identified in screening 29 interleukin and interleukin receptor genes, an average of 1.7 variants per gene. These data are a subset of the results from resequencing over 160 genes with roles in inflammation. Eighty-five variants have been identified in screening 24 drug/carcinogen metabolizing genes for DNA sequence variation, an average of 3.5 variants per gene. (See previously listed websites for current data.) A large data set is available for DNA repair and DNA damage recognition checkpoint genes, where over 450 amino acid substitutions have been identified in resequencing of 85 genes, an average of 5.3 amino acid substitution variants per gene. It should be noted that at least some of the difference in the average number of different amino acid substitution variants per gene could be related to the average size of the coding region for the genes in the different families. Not unlike the catalog of DNA sequence and genes from the Genome Project, the catalogs of variants are available as a starting point for investigators desiring to initiate experiments to address specific hypotheses. Sufficient information is available in the databases to support establishment of genotyping assays and also to infer haplotypes. The availability of these data at the previously mentioned websites is a reflection of the relative ease with which large quantities of data/information, resources available for new experiments by other researchers, can be generated by a relatively small number of laboratories organized to focus on large-scale data generation.
A complimentary effort to identify the majority of the high frequency SNPs across the entire human genome, undertaken by the SNP Consortium, resulted in identification of some 1.42 million SNPs (Sachidanandam et al., 2001) . Most of these SNPs are not within coding regions of genes, but the highly polymorphic SNPs in this collection have been an important resource for building high-density genetic maps that can support efforts to map, identify and characterize genes associated with complex human diseases. Examples of both the strategies and the problems involved in identifying genetic variation with roles in complex diseases can begin to be appreciated from recent papers describing efforts to identify genes associated with risk for prostate cancer (Nwosu et al., 2001) , type 2 diabetes (Cox et al., 2001) and asthma (Xu et al., 2001) . Understanding diseases with complex patterns of inheritance and an exposure relationship is very important as these diseases account for a large fraction of the disease burden in the population. The following discussion will focus on the role of common polymorphisms in DNA repair genes and cancer risk.
DNA Damage and DNA Repair Pathways
The relationship of variation in DNA repair and cancer risk provides an opportunity to highlight some of the issues and obstacles in fully implementing a Genotype to Phenotype paradigm. DNA is routinely assaulted by intracellular and environmental agents that cause a wide range of damage (Lindahl, 1993; Friedberg et al., 1995; Povirk, 1996) . The pattern of DNA damage induced by an agent is often complex. Although the spectrum of damage may have characteristics associated with the damaging agent, the damage does not usually provide a unique "signature" that can be employed for identifying exposure to a specific agent. A range of covalently bound DNA adducts and DNA strand breaks can be detected in cells following environmental or lifestyle exposures or treatment with pharmaceutical agents (Garner, 1998; Airoldi et al., 1999; Phillips et al., 2000) . Many of these DNA adducts can be identified in tissues from nominally unexposed individuals (Gupta and Lutz, 1999; Povey, 2000) . Although these exposures are important, the major DNA damaging agents are reactive oxygen species generated during normal cellular metabolism, with additional contributions from errors occurring during normal DNA replication. Thus, even in the absence of exposures, cells must constantly deal with a large number and wide range of premutagenic lesions in their DNA and estimates of cancer risk from exposures must account for this background or spontaneous damage.
The DNA "damage" intermediates or lesions existing at the time of DNA replication and cell division leads to the accumulation of nucleotide sequence changes and chromosome aberrations (mutations). To deal with this damage, organisms have four major, generally non redundant, pathways for repairing different DNA lesions and classes of damages DNA. It is critical that DNA lesions be repaired prior to replication and cell division to prevent transfer of genetic damage and mutations to daughter cells. Thus, the DNA Damage Recognition Checkpoint genes also have important roles in the repair of DNA damage by directing cell responses to limit the consequences of induced DNA damage. These pathways involve the interaction and sequential activity of multiple proteins. Over 150 genes encode proteins with roles in one or more of these pathways (Wood et al., 2001; Bernstein et al., 2002; . All of the proteins in these pathways must function efficiently to accurately repair DNA damage prior to replication in order to ameliorate the consequences of exposure.
Consequences of Defective DNA Repair
The important role of DNA repair in maintenance of genomic integrity is most obvious in cancer families, where the presence of variant alleles of a gene is associated with a high penetrance or risk of cancer. Examples of cancer gene syndromes include the breast cancer families with BRCA1 and BRCA2 mutations (Welsch et al., 2000) , the colon cancer families with mismatch repair gene mutations (Hsieh, 2001) and xeroderma pigmentosum (XP). XP is often considered the prototypic cancer gene syndrome. These individuals are at extreme risk of developing skin cancers following even minimal sunlight exposure as the result of the loss of function of one of 10 genes of the nucleotide excision repair pathway (Hoeijmakers, 2001) . Ataxia telangiectasia, Bloom's Syndrome, Fanconi's anemia, and Nijmegen Breakage Syndromes are other examples of human genetic diseases associated with reduced DNA repair and increased cancer proneness (Thompson and Schild, 2001) . Genetic variation in DNA repair as a risk factor is very apparent in these rare cancer families.
DNA Sequence Variation in DNA Repair Genes
As previous mentioned, over 450 different amino acid substitution variants have been identified in systematic screens of individuals nominally representative of the general U.S. population. The average individual variant allele frequency for amino acid substitution variants in DNA repair genes is approximately 4%. Only 15 of the 450 variants have estimated allele frequencies of over 40%. Only 5% of the variants exist at frequencies of >20% in the current data set and less than 10% of the variant alleles exist at >10% allele frequency. Many variants were detected in only 1 of the 180 chromosome screened, with 70% of the repair gene variants existing at allele frequencies of 2% or less (Mohrenweiser et al., 2002) . But, because there are so many low frequency variants, they contribute significantly to the variation among individuals in the population at these loci. It should be remembered that the estimated allele frequencies do not account for potential differences in allele frequencies among ethnic groups, as the ethnicity of the individuals (samples) from the DNA Polymorphism Discovery Resource is unknown. Some of these variants could exist at high frequency or not be observed at all within specific subpopulations.
The previous discussion pointed out that the repair of damaged DNA requires the activity of proteins functioning in a pathway. The complexity of the problem to be addressed in associating genetic variation with risk becomes apparent when it is realized that these repair pathways require the activity of 20-40 different proteins to complete the repair process. Thus, given the large number of different variant alleles, the typical individuals will be variant for 10-15 proteins required for repair of a specific class of damage. But, these typical individuals will not have similar pathway genotypes as these 10-15 variants will be drawn from a pool of 100-200 different amino acid substitution variants. Although a single susceptibility allele may reduce activity of a protein only marginally, individuals with variants at multiple genes in a pathway may have quite significantly reduced pathway capacity to repair damaged DNA. In the end, it is the integrated activity of the proteins of the relevant pathway that determines susceptibility to health risk from an exposure. Only rarely is the elevated risk the consequence of variation at only one gene. The challenge facing toxicology (and pharmacology) is to develop strategies to utilize the rapidly growing catalogs of the extensive genetic variation among individuals and the resulting complex genotypes to refine the estimates of the health risks from exposure to relevant levels of environmental agents.
DNA Repair Capacity and Cancer Risk
There is no question regarding the role of DNA repair in ameliorating the consequences of DNA damage and minimizing the incidence of cancer. The more challenging question is the quantitative contribution of small to moderate reductions in the ability to repair damaged DNA to risk for the 95% of cancer in the population that is not inherited as a Mendelian trait. In these "noncancer families," the existence of first degree relatives with cancer constitutes a significant risk factor for an individual (Sellers et al., 1992; Peto et al., 1996) . This is taken as evidence for a role for genetic variation in individual susceptibility in sporadic cancer, as the elevated risk can not be entirely explained by shared environment and common exposure (Peterson 2000; Hopper 2001 ). The role of genetic variation in sporadic cancer risk has been directly demonstrated in molecular epidemiology studies, especially in studies of genes responsible for the metabolism and detoxification of chemical carcinogens (Perera, 2000; Shields and Harris, 2000; Rothman et al., 2001) .
Evidence that polymorphic variation in DNA repair genes is associated with disease risk in non-inherited, familial cancer is also accumulating. First, considerable inter-individual variation in the capacity to repair DNA damage is detected using assays where cells are exposed to direct-acting mutagens in vitro and the residual or unrepaired DNA damage is measured at times postexposure. Evidence indicates that much of the interindividual variation, with over 10% of healthy people in the population exhibiting a capacity to repair one class of DNA damage that is only 60-80% that of the population mean (Grossman, 1999) , is genetic in origin. The reduced repair capacity phenotypes for damage induced by different DNA damaging carcinogens behave as independent traits (Wu 1998 (Wu , 1998b , consistent with the expectation that different pathways have primary responsibility for repairing different classes of DNA damage. Also, first-degree relatives of cancer cases exhibit elevated frequency of the reduced repair capacity phenotype ( Patel et al., 1997; Jyothesh et al., 1998; Roberts et al., 1999) , again suggesting that repair TOXICOLOGIC PATHOLOGY capacity is an inherited trait. The most direct evidence for these phenotypes being genetic traits is the estimates of heritability for repair capacity phenotypes that range from 0.65-0.80 (Cloos et al., 1999; Roberts et al., 1999; Wu et al., 2000) .
Many studies have reported relationships between variation in capacity to repair DNA damage and cancer risk (recently reviewed by Berwick et al., 2000 Berwick et al., , 2002 . The studies encompass multiple cancer sites, a suite of repair capacity assays that integrate the capacity of repair pathways to repair damage, and different DNA damaging agents. Small, ∼20-35%, reductions in repair capacity are associated with elevations in cancer risk in the majority of studies, usually with odds ratios in the range of 3-6. Notably, the impact of reduced repair capacity is found in some instances to be greatest at low levels of exposure (Vineis, 1997; Zhang et al., 2000) . The generality of the results lends credibility to the hypothesis that modest differences among individuals in the general population in DNA repair activity affect risk of disease from endogenous and exogenous exposures.
Additional evidence for the importance of moderate reductions in DNA repair capacity in cancer risk is accumulating from gene "knock-out" experiments in mice (Kaina et al., 1998; Ihle 2000; Ishikawa et al., 2001; Meira et al., 2001a Meira et al., , 2001b . Particularly relevant to individual risk and the incidence of cancer in the human population is data from studies of heterozygous knock-out mice. For instance, mice with reduced activity of Fen1 (a gene of the base excision repair pathway) (Kucherlapti et al., 2002) Blm (a helicase with function in the repair of double strand breaks) (Goss et al., 2002) , or Atm (a protein with a role in damage recognition function (Spring et al., 2002) exhibit elevated tumor incidence at older ages. This is consistent with the role of age as a risk factor for cancer in the human population. For some genes (Ape1, Atm, Xpc) the reduced repair capacity was associated with increased risk in the presence of carcinogen exposure (Cheo et al., 2000; Meira et al., 2001a; Worgul et al., 2002) . The results from these model systems, where the mice retain 50% of normal capacity and appear generally healthy, support the conclusion that modest changes in repair capacity are associated with elevated risk from low level exposure and aging, emulating the risk factors for cancer in the human population. Thus, the cumulative evidence supports the conclusion that DNA repair capacity is a highly heritable trait that makes a substantial contribution to individual cancer risk.
UTILIZING GENETIC VARIATION DATA IN RISK ESTIMATES
With the increasing availability of the data from these variation screens, the challenge is selecting the candidate genes most likely to be relevant for a disease and then the subset of polymorphic variants in a gene that are of highest potential to be associated with elevated risk. Obviously, this assumes that not all of the observed amino acid substitutions are neutral and without impact on protein function. Inspection of the variants in repair genes suggests that many of the substitutions have characteristics expected to impact function. Over 70% of the substitutions observed are exchanges of amino acid residues with dissimilar physical and/or chemical properties. Similarly, approximately 70% of the substitutions occur at residues where the common allele is identical in human and mouse. Approximately 50% of the variants have both char-acteristics that would be expected of amino acid substitution variants that impact protein structure and function.
Studies have now begun to more directly address the question of the potential relevance of the polymorphic repair gene variants identified in the general (healthy) population. Hadi et al. (2000) reported that 4 of 8 variants of the base excision repair protein Ape1 had reduced enzymatic activity. Adding to the interest in the role of variation in DNA repair genes is the accumulating evidence that genetic polymorphisms in DNA repair pathway genes are associated with reduced repair capacity. The activity of several common variants has been documented to be less than the wild-type protein in repair assays (Qiao et al., 2002a (Qiao et al., , 2002b Wu et al., 2003) . Although these studies provide important information confirming the impact of polymorphic amino acid substitutions on protein activity, they are not capable of being scaled to accommodate the rapidly increasing number of variants being identified.
To address questions regarding the potential for these polymorphisms to impact protein structure and activity, a number of algorithms have been developed for predicting the impact of amino acid substitutions on protein structure and activity Henikoff, 2001, 2002; Wang and Moult, 2001; Ramensky et al., 2002; Sunyaev et al., 2002) . We have initiated studies with two in silico strategies to explore the question of the functional impact of the amino acid substitution variants observed in the screening of the DNA repair genes in the previously described sample set. The algorithm from the Henikoff group (Ng and Henikoff 2002) weighs the evolutionary conservation of protein sequence heavily, while the PolyPhen (Polymorphism Phenotype) algorithm from the Bork group weighs aspects of the protein structure as annotated in SwissProt more heavily (Sunyaev et al., 2002) . The SIFT (Sorting Intolerant From Tolerant) algorithm of Ng and Henikoff predicts that ∼35% of the common variants in repair genes will have at least a moderate impact on function (SIFT scores of <0.05). An additional 20% of the variants are predicted to have a modest impact (SIFT scores of 0.05-0.10) (Mohrenweiser et al., 2003b) . These 2 classes of variants account for over 50% of the genetic variation among individuals in these genes. Similar projections of the proportion of variants impacting repair protein activity have been obtained for a small set of variants by Savas et al. (2000) . The PolyPhen algorithm also predicts that approximately half of the amino acid substitutions will impact protein structure/function. No association of allele frequency and predicted level of retained activity was observable.
Variation and Biomarkers of Exposure
DNA adducts and DNA damage are measures of endogenous plus exogenous exposure, but the quantitative relationship is complex as large differences in the levels of adducts are noted among individuals with similar exposure histories (Lutz, 1999; Vineis and Perera, 2000; Hemminke et al., 2001) . Chromosomal translocations and gene mutations such as at the HPRT locus are more indirect measures of exposure, but have the potential to be integrating measures of exposure over time and may be more closely related to the biological events leading to tumorogenesis. Again large differences in response are noted among individuals with similar exposures ( Bigbee et al., 1998; Thomas et al., 1999; Jones et al., 2002) . Genetic differences in the ability of cells to metabolically activate and/or detoxify mutagenic agents explain some of the variation observed among individuals with similar exposures (Lutz, 1999; Butkiewicz et al., 2000; Whyatt et al., 2000) . These studies documenting a role for individual differences in response to common exposures begin to provide plausible explanations for the observations that the levels of cytogenetic damage in lymphocytes are better predictors of individual cancer risk than estimators of historical exposure (Hagmar et al., 1998; Bonassi et al., 2000) . This is consistent with the accumulating data indicating that the health consequences of exposure to environmental agents result from the interaction of dose and the genetic constitution of the individual.
Adding to the evidence that common (polymorphic) DNA repair gene variants are functionally relevant are the observations that variants of several DNA repair genes are associated with elevated levels of measures of DNA damage in individuals exposed to carcinogens. The XRCC1 399Gln variant has been associated with phenotypic measures of carcinogen exposure that are expected to reflect individual cancer risk. These phenotypes include increased levels of aflatoxin adducts (Lunn et al., 1999) , increased levels of polyphenol adducts in smokers (Duell et al., 2000) , increased frequency of glycophorin A mutations and sister chromatid exchanges in somatic cells in smokers (Lunn et al., 1999; Duell et al., 2000) . The impact of the substitution of Gln for Lys at position 751 of ERCC2 is difficult to interpret. The ERCC2 751Gln variant is associated with a reduced capacity for repairing UV-induced DNA damage (Moller et al., 2000) , but is protective against basal cell carcinoma (Vogel et al., 2001) . This variant is not associated with differences in level of SCEs or polyphenol adducts in smokers (Duell et al., 2000) .
Repair Gene Variants and Cancer Risk
The most compelling evidence for the functional relevance of the polymorphic variants are the studies of the relationship of amino acid substitution variants in DNA repair genes to cancer risk that are being published. Studies published through mid 2002 have been summarized by Goode et al. (2002) . Reports from similar studies continue to be published (Ahsan et al., 2003; Liang et al., 2003; Ratnasinghe et al., 2003; Smith et al., 2003; Zhou et al., 2003) . Most of these studies have focused on a small number of highly polymorphic variants reported in Shen et al. (1998) and have examined the impact of only individual variants on cancer risk. The odds ratios for the individual variants are in the range of 1.3-2.0 and not all of the studies are consistent with regard to risk association. Individuals with more than one variant allele, either within a gene or among genes, tend to be at higher risk (Hu et al., 2001) . That the risks associated with single SNPs in molecular epidemiology studies are generally less than the risks associated with the reduced repair capacity phenotypes is expected, if one assumes that the repair capacity and mutagen sensitivity phenotypes are the sum of the impact of multiple variants in multiple genes in a pathway.
Relating Complex (Pathway) Genotypes to Cancer Risk
Relating the extensive variation to disease risk for an individual in the population is a major challenge. In an effort to develop approaches for relating complex (pathway) sequence variation to function or intervening measures of disease risk, we have initiated a study of differences in capacity to repair single strand breaks (the primary substrate for the base excision repair (BER) pathway) among cell lines of known genotype. The goal is identification of variants contributing to the variation between individuals in a repair pathway-relevant phenotype in a population of individuals. Note, that with the large number of variants in the genes of a repair pathway, each cell line will have a unique combination of variants and a unique pathway genotype. As a measure of repair pathway activity/capacity, the level of endogenous single strand breaks plus base damage and the rate of repair of this class of DNA damage following exposure of the cells to ionizing radiation were estimated. We applied statistical approaches to identify gene variants contributing to variation in the BER pathway phenotypes (Jones et al., 2003) . The most influential of the 87 amino acid substitutions and 15 SNPs in potential regulatory sequences in the 5 untranslated region in 28 BER genes were identified. Seven of the most influential variants (5 amino acid substitutions and two 5 UTR variants) were found to explain ∼25% of the phenotypic variation between individuals in the endogenous level of breaks. Five variants, (4 amino acid substitutions and one 5 UTR variants) including 2 that were identified as explaining variation in the level of endogenous breaks, explained ∼15% of the variation among individuals in the rate of repair (Jones unpublished) . Consistent with the identification of these variants as being important in explaining variation among individuals in a repair capacity phenotype, all seven of the amino acid substitutions were predicted to impact protein structure with both the SIFT and PolyPhen algorithms. Additional details of this approach are described in .
SUMMARY OF GENETIC VARIATION AND RISK ESTIMATION
In summary, the already extensive lists of common genetic variants will continue to grow. But, progress in the study of the role of genetics in the population incidence of common diseases and traits, often characterized by complex patterns of inheritance (sometimes referred to as non-mendelian inheritance) and gene(s) by environment (or exposure) interaction has been limited. In the several successes in the area of pharmacogenetics described earlier, the aberrant functioning of one gene was sufficient to place an individual at very high risk of adverse response. This is similar to the situation in disease families. This is not the situation for most of the disease burden in the population, where disease risk from exposure for an individual is a consequence of the combination of alleles at several different genes. Predicting risk becomes even more complex when one must account for the level of exposure to disease causing agents. From the exposure perspective, the extensive genetic variation and increasingly apparent variation in susceptibility means that obtaining quantitative estimates of risk from exposures to toxic agent will be very challenging.
In this context, the environmental component or exposure can be uncontrolled (e.g., pollution) or a lifestyle factor (e.g., smoking, diet). These exposures are in addition to DNA damage from endogenous sources. For the more simple Mendelian traits, individuals in a family can usually be divided into high risk and low risk on the basis of genetic variation at a single locus. For complex diseases, an 142 MOHRENWEISER TOXICOLOGIC PATHOLOGY almost continuous gradient of individual risk exists within the population. This will include individuals with reduced susceptibility and other individuals with potentially resistant genotypes. The individual risk will reflect genotypes at multiple loci and the exposure. In these cases, some individuals in the population having the "at-risk" genotype will not exhibit disease because they have not been exposed to levels of toxic agent above a threshold necessary to induce disease, given their genetic constitution and susceptibility. It must also be appreciated that genetics is not the complete story and genetic susceptibility exists in concert with other susceptibility factors such as age and gender. The existence of individuals with disease but with neither obvious genetic risks nor exposure illustrates the difficulty of identifying both the exposure and genetic factors. Nonsmokers have lung cancer, just at a much lower rate than smokers, and some heavy, long-term smokers are apparently disease free, suggestive of a resistance to the consequences of this exposure. Low ability to activate procarcinogens, elevated ability to detoxify DNA damaging compounds and/or high capacity to repair damaged DNA are examples of phenotypes that could be associated with reduced susceptibility to exposure. The problem of identifying the molecular basis for aberrant responses is very (inordinately) complex, especially when the deviation from the mean response is continuous and reflective of small contributions of multiple genes and multiple variants and exposure. Continued development and in some instances entirely new paradigms for experimental approaches and data analysis will be required to address these complex and data intensive problems (Risch, 2000 (Risch, , 2001 Ponder, 2001) . These are problems that must be conquered if the much discussed potential for more individualized risk estimates is to become reality for the exposures and common diseases affecting the population. At the same time, the ethical issues surrounding screening for disease predisposition must be addressed (Lash et al., 2003) .
CHALLENGES OF THE FUTURE
Genetic variation as exemplified by cancer susceptibility alleles is a key element in determining an individual's risk of cancer, even in the absence of the highly penetrant variant alleles observed in cancer families. "Cancer susceptibility" alleles, although increasing risk only a few fold, exist in aggregate at substantial frequency and have the potential to have a major impact on the population incidence of cancer , with only a modest impact on the individual risk. The role of genetics in determining cancer susceptibility does not exclude a role for environmental exposure and lifestyle factors in determining an individual's risk of cancer. It seems apparent that for most of the population, disease risk is the result of the interaction of the altered function/activity expected for the gene products expressed by susceptibility alleles and moderate or even low level exposure to carcinogenic agents.
A challenge for toxicology is to utilize the knowledge of this extensive genetic variation and variation in individual susceptibility in studies of exposure related risk. This will be critical as the science of toxicology increasingly moves towards quantitative estimation of levels of risk and away from cataloging of toxic agents.
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